Ibaraki, Japan

Takashi Ohkura

This inventor holds 3 USPTO granted patents and 1 published patent application and 2 EPO patents. Top assignees: National Institute of Advanced Industrial Science and Technology, Tokyo Medical University, Glycobiomarker Leading Innovation Co., Ltd.. Active years: 2017-2020.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Takashi Ohkura. Retrieved from https://idiyas.com/inventor/takashi-ohkura

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 3 

% Patents Active = 66.7

 

Average Co-Inventor Count = 12.3

ph-index = 1

Forward Citations = 3(Granted Patents)


Location History:

  • Ibaraki, JP (2017)
  • Tsukuba, JP (2020)

Company Filing History:


Years Active: 2017-2020

Loading Chart...
Loading Chart...
3 patents (USPTO):Explore Patents

Title: Takashi Ohkura: Innovator in Glycan Markers for Cancer Diagnosis

Introduction

Takashi Ohkura is a prominent inventor based in Ibaraki, Japan, known for his significant contributions to the field of medical diagnostics. He holds three patents that focus on the development of glycan markers for the diagnosis of lung cancer and hepatic diseases. His work aims to enhance the sensitivity and convenience of cancer diagnosis, providing valuable tools for healthcare professionals.

Latest Patents

One of Ohkura's latest patents is centered on a lung cancer differential marker. The objective of this invention is to develop a marker that allows for the convenient and highly sensitive diagnosis of lung cancer, independent of the fluctuations in protein expression levels between cancer patients and healthy individuals. Additionally, this patent includes the development of a glycan marker capable of distinguishing between different histological types of lung cancer. The research identified specific glycopeptides and glycoproteins whose glycan structures are altered in lung cancer cell culture supernatants, providing a novel approach to lung cancer diagnosis.

Another significant patent focuses on glycan markers as measures of disease states in hepatic diseases. This invention aims to create a glycan marker that can detect hepatic diseases, particularly hepatocarcinoma. The research identifies glycan structures that change specifically due to hepatic diseases, offering new glycan markers that can indicate the progression of these conditions.

Career Highlights

Throughout his career, Takashi Ohkura has worked with esteemed institutions such as the National Institute of Advanced Industrial Science and Technology and Tokyo Medical University. His research has significantly advanced the understanding of glycan markers in the context of cancer diagnosis.

Collaborations

Ohkura has collaborated with notable colleagues, including Hisashi Narimatsu and Akira Togayachi, contributing to the advancement of research in glycan markers and their applications in medical diagnostics.

Conclusion

Takashi Ohkura's innovative work in developing glycan markers for lung cancer and hepatic diseases represents a significant advancement in medical diagnostics. His contributions have the potential to improve the accuracy and efficiency of cancer diagnosis, ultimately benefiting patient care.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…